CGCHealthcare · Drug Manufacturers - Specialty & GenericThe 8 Wall Street analysts covering Canopy Growth Corp. hold a median 12-month price target of $1.24 — +17.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Canopy Growth Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (67): Analysts have, on balance, been raising their forecasts.
Volatility (18): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CGC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +17.6% from it.
Of the 20 most recent actions, 4 moved their price target up and 11 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2025 | Benchmark | Upgrade | Hold | — |
| 27 Mar 2025 | Zuanic & Associates | Initiates | Neutral | — |
| 9 July 2024 | Piper Sandler | Maintains | Underweight | — |
| 15 Sept 2023 | B of A Securities | Maintains | Underperform | $0.56 → $0.66 |
| 12 June 2023 | CIBC | Maintains | Underperformer | $1.75 → $0.50 |
| 2 May 2023 | Piper Sandler | Maintains | Underweight | $2.00 → $1.00 |
| 17 Feb 2023 | Cantor Fitzgerald | Maintains | Neutral | $3.30 → $3.20 |
| 7 Nov 2022 | Cantor Fitzgerald | Maintains | Neutral | $3.05 → $3.30 |
| 2 Nov 2022 | Bernstein | Initiates | Underperform | $1.50 |
| 26 Oct 2022 | Cantor Fitzgerald | Maintains | Neutral | $2.90 → $3.05 |
| 30 Sept 2022 | Barclays | Maintains | Underweight | $3.50 → $2.00 |
| 8 Aug 2022 | Piper Sandler | Maintains | Underweight | $3.00 → $2.50 |
| 30 June 2022 | Piper Sandler | Maintains | Underweight | $4.00 → $3.00 |
| 8 June 2022 | Barclays | Maintains | Underweight | $6.00 → $3.50 |
| 31 May 2022 | Piper Sandler | Maintains | Underweight | $6.00 → $4.00 |
| 22 Mar 2022 | Barclays | Downgrade | Underweight | — |
| 1 Mar 2022 | Barclays | Maintains | Equal-Weight | $14 → $9.00 |
| 18 Feb 2022 | Cantor Fitzgerald | Maintains | Neutral | $9.60 → $11 |
| 22 Dec 2021 | B of A Securities | Downgrade | Underperform | $19 → $10 |
| 20 Dec 2021 | Piper Sandler | Downgrade | Underweight | $11 → $7.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGC appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 57% of US stocks
Cheaper than 77% of US stocks
Cheaper than 86% of US stocks
Higher than 58% of US stocks
Higher than 31% of US stocks
Higher than 21% of US stocks
Higher than 7% of US stocks
Higher than 24% of US stocks
Higher than 33% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Canopy Growth Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Canopy Growth Corp. (CGC) has risen 15% in a month, with its cannabis business showing signs of a turnaround. The rally is fueled by revenue growth, improving margins, and a narrower EBITDA loss.
Why it matters — A CGC watcher would care because these improving fundamentals suggest the company's cannabis operations may be stabilizing after recent struggles.
On Wednesday afternoon, Tilray Brands shares rose 6% to $4.75 as part of a broad bid for beaten-down speculative names, while Canopy Growth climbed 3% and Aurora Cannabis gained 4%. Despite the move, Tilray remains down 47% year-to-date.
Why it matters — The report highlights a broad rally in cannabis stocks, including a 3% gain for Canopy Growth, which is relevant for CGC watchers tracking sector-wide trading momentum.
The article highlights that Canadian cannabis stocks are drawing renewed investor attention as the sector evolves since Canada's 2018 legalization. It notes that several leading companies have emerged stronger after years of restructuring, cost reductions, and increased competition.
Why it matters — CGC watchers would care because the piece signals renewed sector interest and positions leading Canadian operators as having strengthened through restructuring, which is relevant context for Canopy Growth.
Canopy Growth announced that it has mailed its proxy statement and fiscal 2026 annual report to shareholders ahead of its Annual General and Special Meeting, and urged shareholders to vote. The materials were sent either by mail or via a notice of internet availability.
Why it matters — CGC watchers would care because this marks the formal start of the shareholder voting process for the company's upcoming annual and special meeting.
Curaleaf has made a $272 million bid to acquire Aurora Cannabis, a move that signals accelerating consolidation in the cannabis industry. The article notes that Canopy Growth could emerge as another potential takeover target in this environment.
Why it matters — A CGC watcher would care because the article identifies Canopy Growth as a possible candidate in the ongoing wave of cannabis-industry consolidation.
The 8 Wall Street analysts covering Canopy Growth Corp. have a median 12-month price target of $1.24, with estimates ranging from $1.24 to $1.24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Canopy Growth Corp., 2 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Canopy Growth Corp. 48 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Canopy Growth Corp. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (67 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +17.6% from the last close, and Ticker Nerd's factor model ranks Canopy Growth Corp. 48 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Canopy Growth Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.24 to $1.24 over the next 12 months.
Canopy Growth Corp. returned -15.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Canopy Growth Corporation is a cannabis company that develops, cultivates, and sells medicinal and recreational cannabis, hemp, and cannabinoid-based products. Its portfolio includes brands serving adult-use, wellness, and medical consumers, along with products and devices across multiple categories.
The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?". Canopy Growth Corp. (CGC) has risen 15% in a month, with its cannabis business showing signs of a turnaround. The rally is fueled by revenue growth, improving margins, and a narrower EBITDA loss.
Canopy Growth Corporation is a cannabis company that develops, cultivates, and sells medicinal and recreational cannabis, hemp, and cannabinoid-based products. Its portfolio includes brands serving adult-use, wellness, and medical consumers, along with products and devices across multiple categories. The company operates through segments such as Canada cannabis, international cannabis markets, Storz & Bickel, and This Works, reflecting a business model that spans plant-based products, vaporizers, and wellness offerings. Canopy Growth Corporation serves consumers, medical patients, and commercial partners in regulated markets, with a focus on cannabis product development, distribution, and brand differentiation. Headquartered in Smiths Falls, Ontario, Canopy Growth Corporation is positioned as a diversified participant in the global cannabis industry.
CEO Mr. Luc Mongeau · 1,128 employees · Canada · https://www.canopygrowth.com